Stay updated on LN-145 & Durvalumab Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page.

Latest updates to the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page
- Check5 days agoChange DetectedAdded a dedicated Locations section listing California, Kentucky, Michigan, New Jersey, Pennsylvania, Tennessee, and Washington, plus a new revision note (v3.3.3). Removed the individual state location subsections (California Locations, Kentucky Locations, etc.) and the previous revision note (v3.3.2).SummaryDifference0.9%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no changes to study details, eligibility criteria, locations, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange Detected- Removed the government funding/operational status banner; the study details, eligibility criteria, and locations remain unchanged.SummaryDifference0.4%

- Check55 days agoChange DetectedNo significant changes detected between the old and new screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check84 days agoChange DetectedMajor update: adds current operating status notice and links for NIH Clinical Center, and bumps version to v3.2.0, replacing the old v3.1.0.SummaryDifference4%

- Check91 days agoChange DetectedUpdated software version from v3.0.2 to v3.1.0, reflecting a new release without other substantive content changes.SummaryDifference0.1%

Stay in the know with updates to LN-145 & Durvalumab Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page.